← Leaderboards
Kapil N. Bhalla
University Of Tx Md Anderson Can Ctr
$16,921,043
Attributed
$21,470,058
Total exposure
15
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,470,058 · 15
By mechanism
R01$21,470,058 · 15
Top collaborators
- Courtney Dinardo10 shared
- Warren Campbell Fiskus6 shared
- Srdan Verstovsek5 shared
- Koichi Takahashi4 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Roza Insafetdinovna Nurieva$10,025,772
Others in their field
Top investigators on “Apoptosis”
- David Heimbrook · Leidos Biomedical Research, Inc.$49,205,802
- Jay A Nelson · Oregon Health & Science University$45,942,124
- John C Reed · University Of Texas Md Anderson Can Ctr$34,437,189
- John A Tainer · Scripps Research Institute$30,637,655
- Henry Shelton Earp · Univ Of North Carolina Chapel Hill$28,872,594
- John D Minna · University Of Texas Sw Med Ctr/Dallas$27,317,167
Research focus
ApoptosisProteinsIn VitroMediatingIn VivoGrowthBaseMutationCellsAttenuatedMutantInhibitor/AntagonistGenesSignal TransductionRefractoryAnalogResistanceGenetic TranscriptionMessenger RnaHistone Deacetylase InhibitorHistonesPre-ClinicalStem CellsOncogenes
Grant awards (68)
Role of targeting ATPases BRG1/BRM in therapy of AML$542,663
R01 · FY2025 · CA
Biology and novel therapy of AML expressing somatic or germline mutant RUNX1$496,911
R01 · FY2025 · CA · contact PI
Novel combination therapy for AML expressing mutant RUNX1$507,478
R01 · FY2024 · CA
Biology and novel therapy of AML expressing somatic or germline mutant RUNX1$472,065
R01 · FY2024 · CA · contact PI
Targeting dysregulated transcriptome as therapy for post-myeloproliferative neoplasm (MPN) sAML$452,068
R01 · FY2024 · CA · contact PI
Novel combination therapy for AML expressing mutant RUNX1$523,503
R01 · FY2023 · CA
Biology and novel therapy of AML expressing somatic or germline mutant RUNX1$486,972
R01 · FY2023 · CA · contact PI
Targeting dysregulated transcriptome as therapy for post-myeloproliferative neoplasm (MPN) sAML$466,344
R01 · FY2023 · CA · contact PI
Novel combination therapy for AML expressing mutant RUNX1$523,503
R01 · FY2022 · CA
Biology and novel therapy of AML expressing somatic or germline mutant RUNX1$486,972
R01 · FY2022 · CA · contact PI
Targeting dysregulated transcriptome as therapy for post-myeloproliferative neoplasm (MPN) sAML$466,344
R01 · FY2022 · CA · contact PI
Novel combination therapy for AML expressing mutant RUNX1$534,187
R01 · FY2021 · CA
Biology and novel therapy of AML expressing somatic or germline mutant RUNX1$496,911
R01 · FY2021 · CA · contact PI
Targeting dysregulated transcriptome as therapy for post-myeloproliferative neoplasm (MPN) sAML$475,860
R01 · FY2021 · CA · contact PI
BET protein antagonist-based targeted therapy of Mantle Cell Lymphoma$390,134
R01 · FY2021 · CA · contact PI
Targeting dysregulated transcriptome as therapy for post-myeloproliferative neoplasm (MPN) sAML$475,860
R01 · FY2020 · CA · contact PI
BET protein antagonist-based targeted therapy of Mantle Cell Lymphoma$390,134
R01 · FY2020 · CA · contact PI
BET protein antagonist-based targeted therapy of Mantle Cell Lymphoma$378,430
R01 · FY2019 · CA · contact PI
BET protein antagonist-based targeted therapy of Mantle Cell Lymphoma$390,134
R01 · FY2018 · CA · contact PI
BET protein antagonist-based targeted therapy of Mantle Cell Lymphoma$390,134
R01 · FY2017 · CA · contact PI
Targeted Therapy for AML Stem Cells$332,000
R01 · FY2017 · CA · contact PI
Novel Targeted Therapy for AML$332,000
R01 · FY2017 · CA · contact PI
Novel Targeted Therapy for AML$332,000
R01 · FY2016 · CA · contact PI
Targeted Therapy for AML Stem Cells$332,000
R01 · FY2016 · CA · contact PI
Targeted Therapy for AML Stem Cells$332,000
R01 · FY2015 · CA · contact PI
Novel Targeted Therapy for AML$332,000
R01 · FY2015 · CA · contact PI
Targeted Therapy for AML Stem Cells$317,009
R01 · FY2014 · CA · contact PI
Novel Targeted Therapy for AML$317,009
R01 · FY2014 · CA · contact PI
Novel Targeted Therapy for AML$326,813
R01 · FY2013 · CA · contact PI
Targeted Therapy for AML Stem Cells$326,813
R01 · FY2013 · CA · contact PI
Heat shock protein 90 antagonist-based therapy of mantle cell lymphoma$254,721
R01 · FY2012 · CA · contact PI
Heat shock protein 90 antagonist-based therapy of mantle cell lymphoma$47,192
R01 · FY2012 · CA · contact PI
Heat shock protein 90 antagonist-based therapy of mantle cell lymphoma$301,913
R01 · FY2011 · CA · contact PI
Histone Deacetylase Inhibitor Based Therapy of AML$174,533
R01 · FY2011 · CA · contact PI
Histone Deacetylase Inhibitor Based Therapy of AML$74,272
R01 · FY2011 · CA · contact PI
Heat shock protein 90 antagonist-based therapy of mantle cell lymphoma$311,250
R01 · FY2010 · CA · contact PI
Histone Deacetylase Inhibitor Based Therapy of AML$142,857
R01 · FY2010 · CA · contact PI
Histone Deacetylase Inhibitor Based Therapy of AML$111,370
R01 · FY2010 · CA · contact PI
Heat shock protein 90 antagonist-based therapy of mantle cell lymphoma$305,025
R01 · FY2009 · CA · contact PI
Histone Deacetylase Inhibitor Based Therapy of AML$251,370
R01 · FY2009 · CA · contact PI
Histone Deacetylase Inhibitors in CML$200,282
R01 · FY2009 · CA · contact PI
Histone Deacetylase Inhibitors in CML$76,530
R01 · FY2009 · CA · contact PI
Heat shock protein 90 antagonist-based therapy of mantle cell lymphoma$305,025
R01 · FY2008 · CA · contact PI
Histone Deacetylase Inhibitors in CML$275,281
R01 · FY2008 · CA · contact PI
Histone Deacetylase Inhibitor Based Therapy of AML$251,370
R01 · FY2008 · CA · contact PI
Targeting Apoptosis Signaling in Breast Cancer Cells$228,588
R01 · FY2008 · CA · contact PI
Histone Deacetylase Inhibitors in CML$275,281
R01 · FY2007 · CA · contact PI
Histone Deacetylase Inhibitor Based Therapy of AML$251,228
R01 · FY2007 · CA · contact PI
Targeting Apoptosis Signaling in Breast Cancer Cells$228,329
R01 · FY2007 · CA · contact PI
Histone Deacetylase Inhibitors in CML$282,619
R01 · FY2006 · CA · contact PI
Targeting Apoptosis Signaling in Breast Cancer Cells$234,614
R01 · FY2006 · CA · contact PI
Histone Deacetylase Inhibitors in CML$321,925
R01 · FY2005 · CA
Targeting Apoptosis Signaling in Breast Cancer Cells$267,320
R01 · FY2005 · CA
Gleevec plus novel anti-Bcr-Abl strategies in Leukemias$167,389
R01 · FY2005 · CA
Gleevec plus novel anti-Bcr-Abl strategies in Leukemias$156,841
R01 · FY2005 · CA
Gleevec plus novel anti-Bcr-Abl strategies in Leukemias$322,625
R01 · FY2004 · CA
Targeting Apoptosis Signaling in Breast Cancer Cells$267,320
R01 · FY2004 · CA
Control of ARA C Induced Apoptosis of AML Cells$258,100
R01 · FY2004 · CA
Gleevec plus novel anti-Bcr-Abl strategies in Leukemias$322,625
R01 · FY2003 · CA
Control of ARA C Induced Apoptosis of AML Cells$258,100
R01 · FY2003 · CA
Arsenic Based Therapy of Bcr Abl Positive Leukemias$246,151
R01 · FY2003 · CA
Gleevec plus novel anti-Bcr-Abl strategies in Leukemias$322,625
R01 · FY2002 · CA
Control of ARA C Induced Apoptosis of AML Cells$258,100
R01 · FY2002 · CA
Arsenic Based Therapy of Bcr Abl Positive Leukemias$246,151
R01 · FY2002 · CA
TAXANE INDUCED APOPTOSIS--REGULATION IN BREAST CA CELLS$191,851
R01 · FY2002 · CA
Arsenic Based Therapy of Bcr Abl Positive Leukemias$279,901
R01 · FY2001 · CA
TAXANE INDUCED APOPTOSIS--REGULATION IN BREAST CA CELLS$181,094
R01 · FY2001 · CA
CONTROL OF ARA-C-INDUCED APOPTOSIS OF AML CELLS$192,039
R01 · FY2000 · CA